What are your top takeaways in Breast Cancer from ASCO 2022?  

DESTINY-Breast04: it is phase III study of Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice in HER2-low metastatic breast cancer (MBC). This study showed improved progression-free survival (PFS) and overall survival (OS) with T-DXd vs standard therapy in this patient populat...

DESTINY-Breast-04 is practice changing. In this study, the novel antibody-drug conjugate Trastuzumab deruxtecan outperformed physicians' choice of chemotherapy for patients with pretreated, metastatic HER2 low expressing breast cancer (IHC 1+ or IHC 2+ with negative FISH). There was a significant ...

Whelan T et al. LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). (abstr LBA501) - The LUMINA single-arm prospective trial found that the local recurrence rate at 5 years was 2.3% following partial mastectomy and ...

DESTINY-Breast04 - Takeaway: Clinically meaningful OS benefit and superior ORR over SOC chemotherapy in previously treated HER 2 low MBC (HER 2 IHC 1+ or 2+ with negative FISH) MBC. This makes TDxd a suitable treatment choice for a vast majority of patients with MBC independent of receptor subtype...

LBA3 - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. One of the biggest benefits we have ever seen in HR+ disease w...

DESTINY-Breast04: which showed PFS benefit of Trastuzumab deruxtecan over traditional chemo in HER2 low positive (IHC +1, +2 but FISH negative) patients. This study expands the use of Trastuzumab deruxtecan to another 50% of patients who normally will not be offered an anti-HER2 therapy. MAINTAIN...

DESTINY-Breast04 - We will have a new systemic therapy option for those with HER2 low disease which is urgently needed. LUMINA study - Important that we can possibly de-escalate radiation in patients 55 and older with luminal A tumors. KEYNOTE 522 and RCB analysis - Important additional analysis...

DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice in patients with HER2-low metastatic breast cancer. This is the first phase 3 trial of HER2-directed therapy in patients with HER2-low metastatic breast cancer to show a statistically significant and...

DESTINY-Breast04 is quickly actionable. IHC was designed to identify the HER-2 high (IHC 3+) for trastuzumab. Was never for identifying 0 from 1+. A lot of variability here. Need to discuss 1+ as being actionable with our pathologists. Many I have talked to think that most tumors will have 1+ with...

DESTINY-Breast04 - TDxd clearly much better with impressive clinically relevant differences over TPC (capecitabine, eribulin, gemcitabine, taxane) in both ER+ and TNBC cohorts. Although the numbers with TNBC were small, the results were equally impressive in this cohort of 60 patients. Results are...

Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study - The significant improvement in PFS and OS comparing T-DXd and SOC ch...

DESTINY-Breast04: the role of T-DXd in the treatment of HER2 low breast cancer: practice changing trial showing that patients with tumors Her2 1+ and 2+ can benefit from the use of T-DXd. TROPiCS-02: the role of sacituzumab govitecan in patients with metastatic ER+ breast cancer showing that this...